<DOC>
	<DOCNO>NCT00294190</DOCNO>
	<brief_summary>This propose phase II trial investigate weekly topotecan high dose use previous trial attempt achieve improve response rate disease control without added toxicity . To help ameliorate fatigue , plan rest week incorporate schedule . This trial first clinical trial evaluate high dose weekly topotecan treatment extensive-stage SCLC .</brief_summary>
	<brief_title>Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer</brief_title>
	<detailed_description>All patient receive weekly topotecan . Topotecan 6mg/m2 IV weekly x 6 consecutive week follow 2 week break . Cycles repeat every 8 week , 3 cycle . Restaging study perform every cycle ( 8 week . )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Extensive small cell lung cancer progression one previous chemotherapy chemotherapy/radiation therapy regimen Measurable evaluable disease Able perform activity daily live minimal assistance Adequate bone marrow , liver kidney function May receive 3 previous course radiation therapy Give write informed consent prior study entry Patients limited stage disease History prior malignancy within three year Female patient pregnant breast feed Significant history uncontrolled cardiac disease Myocardial infarction stroke within six month Symptomatic peripheral vascular disease CNS involvement Serious active infection underlie medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Extensive stage</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
</DOC>